THE OFF-LABEL USE OF ATYPICAL ANTIPSYCHOTICS AND ITS IMPACT ON ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)
Atypical antipsychotics (AAPs) (also known as second-generation antipsychotics) are the US Food and Drug Administration (FDA) approved medications for schizophrenia, bipolar I disorder, depression and autism. Compared to the typical antipsychotics, AAPs were marketed as reducing adverse side effects...
Main Author: | Sohn, Minji |
---|---|
Format: | Others |
Published: |
UKnowledge
2014
|
Subjects: | |
Online Access: | http://uknowledge.uky.edu/pharmacy_etds/33 http://uknowledge.uky.edu/cgi/viewcontent.cgi?article=1035&context=pharmacy_etds |
Similar Items
-
Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics
by: Samantha Alvarez-Herrera, et al.
Published: (2020-04-01) -
Hematological Side Effects of Atypical Antipsychotic Drugs
by: Serap Erdogan
Published: (2009-10-01) -
Self-limiting atypical antipsychotics-induced edema: Clinical cases and systematic review
by: Musa Usman Umar, et al.
Published: (2016-01-01) -
Working memory functioning in children with predominantly Inattentive Attention Deficit/Hyperactivity Disorder (ADHD) versus children with predominantly hyperactive ADHD
by: Allsopp, Karen Margaret
Published: (2009) -
Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences
by: Marco Carli, et al.
Published: (2021-03-01)